IPPC 2023: Kedrion alongside PPTA
The Congress brought together policymakers, stakeholders, patient groups and industry in Europe
Kedrion’s global portfolio expands to China to supply human Albumin
This is the first ever approval for a BPL product in China
2023 ISTH Congress, Kedrion confirms its commitment to rare and ultra-rare diseases
Kedrion Biopharma and BPL participated in the 2023 ISTH Congress.
KEDPLASMA Announces Nationwide Facility Remodeling Project
The project aims to enhance the experience of its donors and raise the standard of excellence in its collection centers.
The Fifth John Gorman Lectureship at the “Birth 2022 Congress”
These Conferences in Transfusion Medicine are made possible thanks to the unconditional support of Kedrion Biopharma
Permira Funds and the Marcucci family complete investment in Kedrion & BPL
Announced appointment of Ugo Di Francesco as CEO
Kedrion Biopharma Recognized for Innovation in Treating Rare Disease
RYPLAZIM® is the first FDA Approved Treatment for Plasminogen Deficiency Type 1
Kedrion Biopharma Extends Contract Manufacturing Agreement (CMA) for GAMMAKED in the US, Ensuring Availability to Patients
Kedrion Biopharma will continue to market and distribute GAMMAKED in the U.S. through end of 2025
Kedrion Biopharma to commercialize RYPLAZIM® in U.S
RYPLAZIM® (plasminogen, human-tvmh) will address needs in patients with ultra-rare condition Plasminogen Deficiency Type 1
Kedrion grows in North America as it completes acquisition of Prometic
Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency